MAIA BiotechnologyMAIA
About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Employees: 13
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
2.07% less ownership
Funds ownership: 8.21% [Q2] → 6.14% (-2.07%) [Q3]
19% less funds holding
Funds holding: 21 [Q2] → 17 (-4) [Q3]
32% less capital invested
Capital invested by funds: $6.11M [Q2] → $4.15M (-$1.96M) [Q3]
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for MAIA.
Financial journalist opinion
Based on 4 articles about MAIA published over the past 30 days